Abstract
The discovery of endothelin (ET) in 1988 has led to considerable effort to unravel its implication in health and disease and the mechanisms evoked by ET. ET-1 and related signaling aberrancies are believed to be implicated in the pathogenesis of diverse cardiovascular diseases, such as hypertension, atherosclerosis, hypertrophy and diabetes. The endothelin system consists of three potent vasoconstrictive isopeptides, ET-1, ET-2 and ET-3, signaling through two G protein coupled receptors, ETA and ETB, which are linked to multiple signaling pathways. Activated signaling transduction pathways include the modulation of the adenylyl cyclase/cAMP pathway through stimulatory (Gs) and inhibitory (Gi) G proteins, activation of the phosphoinositide pathway through the activation of proteins Gq/11, generation of oxidative stress, growth factor receptor-related mitogenic events, such as the activation of phosphatidylinositol-3 kinase pathway, phosphoinositide pathway and activation of the mitogen-activated protein (MAP) kinase cascade. The levels of ETA and ETB receptors as well as the signaling pathways activated by these receptors are altered in several cardiovascular diseases including hypertension, hypertrophy, atherosclerosis, diabetes, etc. In this review, we provide an overview of the signaling events modulated by ET-1 in vascular smooth muscle cells in both physiological and pathological conditions.
Keywords: atherosclerosis, diabetes, hypertension, ETA/B receptors, ET-1, ET-1 signaling, ET-1 synthesis.
Current Vascular Pharmacology
Title:Endothelin-1 Signaling in Vascular Physiology and Pathophysiology
Volume: 12 Issue: 2
Author(s): Yessica-Haydee Gomez Sandoval, Mohammed Emehdi Atef, Louis-Olivier Levesque, Yuan Li and Madhu B. Anand-Srivastava
Affiliation:
Keywords: atherosclerosis, diabetes, hypertension, ETA/B receptors, ET-1, ET-1 signaling, ET-1 synthesis.
Abstract: The discovery of endothelin (ET) in 1988 has led to considerable effort to unravel its implication in health and disease and the mechanisms evoked by ET. ET-1 and related signaling aberrancies are believed to be implicated in the pathogenesis of diverse cardiovascular diseases, such as hypertension, atherosclerosis, hypertrophy and diabetes. The endothelin system consists of three potent vasoconstrictive isopeptides, ET-1, ET-2 and ET-3, signaling through two G protein coupled receptors, ETA and ETB, which are linked to multiple signaling pathways. Activated signaling transduction pathways include the modulation of the adenylyl cyclase/cAMP pathway through stimulatory (Gs) and inhibitory (Gi) G proteins, activation of the phosphoinositide pathway through the activation of proteins Gq/11, generation of oxidative stress, growth factor receptor-related mitogenic events, such as the activation of phosphatidylinositol-3 kinase pathway, phosphoinositide pathway and activation of the mitogen-activated protein (MAP) kinase cascade. The levels of ETA and ETB receptors as well as the signaling pathways activated by these receptors are altered in several cardiovascular diseases including hypertension, hypertrophy, atherosclerosis, diabetes, etc. In this review, we provide an overview of the signaling events modulated by ET-1 in vascular smooth muscle cells in both physiological and pathological conditions.
Export Options
About this article
Cite this article as:
Sandoval Gomez Yessica-Haydee, Atef Emehdi Mohammed, Levesque Louis-Olivier, Li Yuan and Anand-Srivastava B. Madhu, Endothelin-1 Signaling in Vascular Physiology and Pathophysiology, Current Vascular Pharmacology 2014; 12 (2) . https://dx.doi.org/10.2174/1570161112666140226122054
DOI https://dx.doi.org/10.2174/1570161112666140226122054 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Leptin as Clinical Target
Recent Patents on Inflammation & Allergy Drug Discovery Bedtime Hypertension Chronotherapy: Concepts and Patient Outcomes
Current Pharmaceutical Design Treatment of Hypertension to Prevent Atrial Fibrillation
Current Pharmaceutical Design Subject Index to Volume 9
Current Pharmaceutical Design Genetic Lipodystrophies: Models for Insulin Resistance
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents COVID-19 Pandemic: Current Scenario, Challenges and Future Perspectives
Coronaviruses Pharmacological Effects of RAAS Blockade in Ischemic Nephropathy
Current Drug Metabolism Development and Characterization of Nasal Delivery of Selegiline Hydrochloride Loaded Nanolipid Carriers for the Management of Parkinson’s Disease
Central Nervous System Agents in Medicinal Chemistry Endothelial Progenitor Cells as a Therapeutic Approach for Intracerebral Hemorrhage
Current Pharmaceutical Design Metabolic and Cardiovascular Complications of Highly Active Antiretroviral Therapy for HIV Infection
Current HIV Research Introduction (Transient Receptor Potential TRP Channels as Therapeutic Drug Targets: Next Round!)
Current Topics in Medicinal Chemistry ENaC Modulators and Renal Disease
Current Molecular Pharmacology Is the Hepatic Factor a miRNA that Maintains the Integrity of Pulmonary Microvasculature by Inhibiting the Vascular Endothelial Growth Factor?
Current Cardiology Reviews D Allele Frequency in Insertion/Deletion Polymorphism of the Angiotensin Converting Enzyme (ACE) Gene is Associated with Development of Breast Cancer Risk in Indian Women
Current Proteomics Chemistry-based Design of Inhibitors for Carboxypeptidase A
Current Topics in Medicinal Chemistry Recent Advances in Developing Ophthalmic Formulations: A Patent Review
Recent Patents on Drug Delivery & Formulation Selective Inhibition of Neuronal Nitric Oxide Synthase by L-Arginine Derivatives
Letters in Drug Design & Discovery Improving the Efficiency and Safety of Aspirin by Complexation with the Natural Polysaccharide Arabinogalactan
Current Drug Delivery Investigating Drug Repositioning Approach to Design Novel Prodrugs for Colon-specific Release of Fexofenadine for Ulcerative Colitis
Current Drug Delivery New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry